News | December 05, 2021
Lupin and Biomm tie-up for pegfilgrastim in Brazil
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The week-long campaign received a record 17.691 pledges
Subscribe To Our Newsletter & Stay Updated
